Article · UK Corporate Tax & R&D
How the 20% above-the-line credit, 15.00% vs. 16.20% effective rates, and CTA 2009 s. 1042I seven-step discharge work in practice
For accounting periods beginning on or after 1 April 2024, Finance Act 2024 Schedule 1 replaced the legacy UK SME and RDEC regimes for most companies with a single unified Merged RDEC Scheme under CTA 2009 Part 13, Chapter 1A (sections 1042A to 1042N). The headline rate is 20% of qualifying R&D expenditure (s. 1042G), brought into account above the line as a taxable trading receipt (s. 1042H).
Because Merged RDEC is taxable above the line (s. 1042H), the net cash or tax benefit depends on the company's Corporation Tax band or loss-making status:
| Taxpayer Profile | Tax / Step 2 Rate | Net Immediate Benefit |
|---|---|---|
| Profitable - Main CT Rate (> £250,000) | 25% | 15.00% |
| Profitable - Small Profits Rate (<= £50,000) | 19% | 16.20% |
| Profitable - Marginal Relief Band (£50,000 to £250,000) | 26.5% | 14.70% |
| Loss-Making or Small-Profits Step 2 (<= £50,000) | 19% (s. 1042K(5)) | 16.20% |
Crucially, CTA 2009 section 1042K(5) applies the 19% small profits rate at Step 2 for both loss-making companies and profitable companies within the £50,000 small profits limit, while section 1042K(2) caps the Step 2 notional tax deduction at max(0, Remaining After Step 1 - Gross RDEC x (1 - Step 2 Rate)) so real CT paid at Step 1 is never double-taxed. Moreover, Finance Act 2024 abolished subsidised expenditure restrictions across both Merged RDEC and ERIS.
Northbridge Photonics Ltd incurs £3,380,000 in gross R&D spend during FY2025. After the 65% unconnected subcontractor/EPW factor and excluding £200,000 paid to a cost-driven Indian subcontractor under section 1138A(4) (while retaining £104,000 for exempt German regulatory testing under s. 1138A(2)), qualifying R&D is £2,900,000, generating a 20% gross Merged RDEC of £580,000.
| CTA 2009 s. 1042I Seven-Step Waterfall | Scenario A1 (£4,200,000 Profit) | Scenario A2 (-£200,000 Loss) |
|---|---|---|
| Baseline CT Without RDEC (25%) | £1,050,000 | £0 |
| Post-RDEC Taxable Profit (+£580,000, s. 1042H) | £4,780,000 | £380,000 |
| Post-RDEC Gross CT Liability (25%) | £1,195,000 | £95,000 |
| Step 1: Current-Period CT Offset (s. 1042I) | £580,000 | £95,000 |
| Net CT Payable to HMRC | £615,000 | £0 |
| Step 2: Notional Tax Withheld (s. 1042K(2) at 25%, CF s. 1042L) | £0 | £50,000 |
| Step 3: PAYE/NIC Cap Restriction (Cap: £1,940,000) | £0 | £0 |
| Steps 4-6: Other CT / Group / Other HMRC | £0 | £0 |
| Step 7: Immediate Cash Refund | £0 | £435,000 |
| Immediate Benefit (CT Saved + Cash) | £435,000 (15.00%) | £435,000 (15.00%, +£50,000 CF) |
Never confuse Step 2 and Step 3 carry-forwards. Northbridge Scenario A2's £50,000 Step 2 pool (s. 1042L) can only offset future Corporation Tax (or be surrendered immediately to a 75% UK group company under s. 1042N) and can never become cash. By contrast, a Step 3 PAYE/NIC cap carry-forward (s. 1042J(2)) rolls into Step 1 of the next accounting period (excluded from a second Step 2 charge under s. 1042K(9)) and can convert into Step 7 cash once PAYE/NIC headroom is restored.
Run your own UK R&D figures through the live 7-step Merged RDEC, ERIS 30% intensity, and PAYE/NIC cap model in UK_RD_Merged_RDEC_ERIS_Calculator.xlsx, or read the complete 15-chapter practitioner reference in The UK R&D Tax Relief Handbook.
Next: UK ERIS 30% R&D Intensity Test and 14.5% Payable Credit
Also read: UK R&D Contracted-Out Rules, Overseas Restrictions, and PAYE/NIC Cap
Related UK corporate tax handbooks: UK Corporate Interest Restriction · UK VAT Partial Exemption · OECD Pillar Two